Business Description
Minerva Neurosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US6033802058
Total Employee Number:
7Description
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -2.7 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -95.7 | |||||
3-Year EPS without NRI Growth Rate | 32.4 | |||||
3-Year FCF Growth Rate | 29.8 | |||||
3-Year Book Growth Rate | 4.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 35.76 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.23 | |||||
9-Day RSI | 41.6 | |||||
14-Day RSI | 42.71 | |||||
3-1 Month Momentum % | -37.74 | |||||
6-1 Month Momentum % | -5.84 | |||||
12-1 Month Momentum % | 110.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 17.65 | |||||
Quick Ratio | 17.65 | |||||
Cash Ratio | 17.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -100.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -732.56 | |||||
ROIC % | -179.75 | |||||
3-Year ROIIC % | -366.96 | |||||
ROC (Joel Greenblatt) % | -9425938.46 | |||||
ROCE % | -568.59 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.39 | |||||
EV-to-EBITDA | -0.39 | |||||
EV-to-Forward-Revenue | 0.03 | |||||
EV-to-FCF | -8.13 | |||||
Earnings Yield (Greenblatt) % | -256.41 | |||||
FCF Yield % | -7.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NERV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Minerva Neurosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -29.16 | ||
| Beta | 1.12 | ||
| 3-Year Sharpe Ratio | 0.26 | ||
| 3-Year Sortino Ratio | 0.49 | ||
| Volatility % | 119.88 | ||
| 14-Day RSI | 42.71 | ||
| 14-Day ATR ($) | 0.423802 | ||
| 20-Day SMA ($) | 4.618 | ||
| 12-1 Month Momentum % | 110.55 | ||
| 52-Week Range ($) | 1.76 - 12.46 | ||
| Shares Outstanding (Mil) | 46.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Minerva Neurosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Minerva Neurosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 110 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 27 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 16:20 | 4.68 (+0.97%) | ||
| General meeting for 2026 | 2026-06-03 08:30 | 4.75 (-0.63%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 6.33 (+4.11%) | ||
| Guidance call for 2026 | 2026-03-18 08:30 | 7.85 (+1.42%) | ||
| Annual report for 2025 | 2026-03-11 | 7.94 (+3.25%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-11 | 7.94 (+3.25%) | ||
| Citizens Life Sciences Conference | 2026-03-10 09:35 | 8.00 (+32.89%) | ||
| virtual key opinion leader (KOL) event | 2026-02-03 10:30 | 4.68 (+13.59%) |
Show
Entries
Minerva Neurosciences Inc Frequently Asked Questions
What is Minerva Neurosciences Inc(NERV)'s stock price today?
The current price of NERV is $4.27. The 52 week high of NERV is $12.46 and 52 week low is $1.76.
When is next earnings date of Minerva Neurosciences Inc(NERV)?
The next earnings date of Minerva Neurosciences Inc(NERV) is 2026-08-14 Est..
Does Minerva Neurosciences Inc(NERV) pay dividends? If so, how much?
Minerva Neurosciences Inc(NERV) does not pay dividend.
Guru Commentaries on NAS:NERV
No articles.
Press Release
Articles on Minerva Neurosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers